Últimas noticias sobre Oruka Therapeutics (NASDAQ:ORKA) Bolsa

ORUKA THERAPEUTICS INC

Oruka Therapeutics

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

GameStop Corp.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BHIL

BSGM

CISO

CLEU

GDHG

HUMA

IMTE

NYXH

ORKA

PTPI

RAPP

SURG

THTX

TXMD

WINT

ZYBT

El premercado de hoy revela fuertes movimientos bursátiles tras informes financieros y aprobaciones clave en sectores críticos.

Las acciones de GameStop (GME) suben alrededor del 13%; Aquí están 20 acciones que se mueven en el premercado

APLD

AZTR

CRKN

CVGW

GCTK

GLAC

HSDT

LFWD

MASS

QBTS

QUBT

RIME

SGBX

VMAR

VRME

Descubre las acciones ganadoras y perdedoras en el premercado, con Vision Marine liderando un aumento del 45%.

Las acciones de Vision Marine (VMAR) se disparan un 45%; 20 acciones que se están moviendo en premercado

Oruka Therapeutics Inc

Channel Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#NASDAQ">CHRO</a>) shares surged on Friday following the announcement of a reverse stock split designed to support its upcoming corporate transformation and meet <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46138428/channel-therapeutics-announces-reverse-common-stock-split-in-conjunction-with-the-close-of-the-mer" rel="noreferrer noopener">exchange listing requirements</a>.
The clinical-stage biotech company, focused on developing non-opioid treatments for pain, revealed a 10-for-1 reverse stock split of its common shares.
The move aims to boost the per-share trading price and align with NYSE American listing standards ahead of a proposed merger with LNHC, Inc. and an associated $50 million capital infusion led by Murchinson.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/06/46140911/healthcare-ai-draws-major-funding-bucking-market-uncertainty" rel="noreferrer noopener">Healthcare AI Draws Major Funding, Bucking Market Uncertainty</a>
The reverse stock split will become effective on July 1, 2025, before the market opens. Trading of the adjusted shares is set to begin the following day, July 2, under the new name Pelthos Therapeutics Inc.
While the company&#8217;s ticker symbol will initially remain &#8220;CHRO,&#8221; it will change to &#8220;PTHS&#8221; upon the closing of the merger.
As a result of the split, shareholders will receive one new share for every 10 currently held, reducing outstanding shares from about 6.5 million to approximately 648,500. Importantly, ownership percentages for shareholders will not be affected, and fractional shares will be rounded up.
Stockholders with book-entry holdings or those using brokers do not need to take any action.
The company&#8217;s transfer agent, Nevada Agency and Transfer Company (NATCO), will provide details about the changes in share ownership following the split.
Price Action: CHRO shares are trading higher by 2.56% to $1.200&nbsp;at last check Friday.
Image via Shutterstock

Equities

General

CHRO

Why Is Channel Therapeutics Stock Surging On Friday?

Macro Economic Events

Market Summary

Economics

Benzinga Market Summary: S&P Rises On US-China Trade Framework, Gold Pulls Back, Nike Rises On Earnings Report

Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) with a Overweight and raises the price target from $313 to $330.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on BeOne Medicines, Raises Price Target to $330

Commodities

Opinion

Natural Gas Demand Set to Surge As Weather And Storage Levels Impact US And Europe

Morgan Stanley analyst James Faucette maintains Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Equal-Weight and lowers the price target from $150 to $148.

PAYX

Morgan Stanley Maintains Equal-Weight on Paychex, Lowers Price Target to $148

Morgan Stanley analyst Megan Alexander maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Underweight and lowers the price target from $51 to $49.

Morgan Stanley Maintains Underweight on General Mills, Lowers Price Target to $49

Morgan Stanley analyst Bob Huang maintains Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) with a Overweight and raises the price target from $37 to $40.

CRBG

Morgan Stanley Maintains Overweight on Corebridge Financial, Raises Price Target to $40

Morgan Stanley analyst Christopher Snyder maintains Acuity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) with a Overweight and raises the price target from $335 to $365.

Morgan Stanley Maintains Overweight on Acuity, Raises Price Target to $365

Most 11-year-olds are worried about math homework. Mallory Marshall was asking <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/06/46067598/bill-gates-kids-were-stunned-to-find-warren-buffett-chowing-down-on-oreos-for-breakfast-after-a-sleepover-naturally-they-demanded-some-too">Warren Buffett</a> how to build wealth. And Buffett—never one to miss an opportunity for both wisdom and a one-liner—delivered.
At the 2001 Berkshire Hathaway meeting, Mallory stepped up to the mic and opened with a crowd-pleaser:
"First, my dad would like to know if you have any grandsons my age."
Buffett didn't hesitate:
"How many shares of stock do you have? And I'll tell you."
Don't Miss:
<ul class="wp-block-list">
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
He added, "I've got a grandson fairly close to your age and he probably would go for a younger woman anyway… I will mention you to him."
But once the laughter faded, Mallory hit him with the real question:
"What investment advice do you have for young people of my generation?"
Buffett's answer wasn't about stock picks or complex finance. It was about having a head start—and knowing what to do with it.
"I was fortunate in that respect because my dad paid for my education. If he hadn't, I probably wouldn't have become educated if I had to pay for it myself… So I was able to save $10,000 by the time I was 21. And, you know, that was a huge, huge head start."
Trending: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
"It's much easier to save in those teenage years if you're lucky enough to be in a family where… your parents are taking care of your financial obligations. Every dollar then is, you know, worth making $10 or $20 later on."
"You have to have a little money to work with," he said. But what you do with it—that's the kicker.
His <a href="https://www.benzinga.com/personal-finance/25/02/43718032/warren-buffett-was-asked-how-a-regular-person-gets-rich-he-detailed-exactly-how-hed-make-30-billion-starting-over-with-only-10000">blueprint was simple</a>:
"Read financial publications. I'd be curious about how the businesses around the town of Kearney operated. Learn about who's got good businesses… and the businesses that went out of business and why."
"Everything is cumulative," Buffett added. "The stuff I learned when I was 20 is useful today… You're building a database in your mind that is going to pay off over time."
He even squeezed in a bit of practical advice for anyone with a wallet:
"There's nothing like getting a few dollars ahead. Stay away from credit cards."
Charlie Munger, ever the realist, chimed in with:
"Well, I'm glad to see somebody that has, so early, shown an interest in getting ahead. There's nothing wrong with getting ahead."
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
Then the two couldn't help circling back to the matchmaking suggestion.
"Actually, she may have the best idea about getting ahead by learning the name of my grandson," Buffett joked.
Munger added, "Before your feelings totally take over, you should <a href="https://www.benzinga.com/personal-finance/24/07/39963533/warren-buffett-says-the-most-important-decision-of-your-life-is-who-you-marry-his-biggest-mistak">look carefully at both parents</a> and all four grandparents."
And Buffett signed off with, "Write Charlie and let us know how it works out."
Now, of course, you can't control who your grandparents are. Buffett himself has famously called this the "ovarian lottery"—the idea that so much of your life's outcome is determined by the luck of birth. And he's not wrong. You don't get to pick your starting line.
But you do get to <a href="https://www.benzinga.com/general/education/25/05/45607543/warren-buffett-you-can-make-a-fortune-but-your-life-is-a-disaster-if-you-overlook-this-one-thing">pick how you run the race</a>. You can build that mental database. You can read, ask questions, stash cash, and skip the credit cards.
And maybe — just maybe — ask about the grandkids.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.

Personal Finance

Warren Buffett Told 11-Year-Old She Could Get Ahead In Life By Marrying His Grandson — Then Dropped Some Real Get-Rich Advice

Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.9%. Currently, Progressive has a market capitalization of $154.56 billion. 
Buying $1000 In PGR: If an investor had bought $1000 of PGR stock 5 years ago, it would be worth $3,363.01 today based on a price of $263.66 for PGR at the time of writing.
<h3>Progressive's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751039111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Progressive Stock In The Last 5 Years

WIIM

AMIX

Autonomix Medical shares are trading higher after the company announced it was granted a US Patent for its catheter-based platform technology.

EXOZ

ExoZymes shares are trading higher after the company announced it has been selected as a core industry partner in a $9 million NSF-funded initiative to advance modular cell-free biomanufacturing.

Morgan Stanley analyst Alex Straton maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Equal-Weight and raises the price target from $61 to $64.

Morgan Stanley Maintains Equal-Weight on Nike, Raises Price Target to $64

RDZN

Roadzen shares are trading higher after the company reported better-than-expected Q4 EPS results.

Time Magazine&#8217;s annual 100 Most Influential Companies list for 2025 includes many companies investors are familiar with, with numerous names originating from the growing <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence sector.</a>
The <a href="https://time.com/7297630/time-reveals-the-2025-time100-most-influential-companies-in-the-world/">list</a> seeks to honor the top businesses that are helping "chart an essential path forward."
"No single data point or financial metric makes a TIME100 Company. Instead, we looked at a mosaic of qualities, studying impact, innovation, ambition, and success, each in the forms that take shape today. And as we say for all TIME100 projects: influence comes in many forms, for better and for worse," Time editors said of the list.
 The Public Companies: Similar to the list of the <a href="https://www.benzinga.com/general/entertainment/25/04/44854679/time-100-most-influential-people-includes-elon-musk-mark-zuckerberg-alex-karp-and-more-public-company-ceos">Most Influential People</a> that Time published earlier this year, the list of influential companies includes top tech, AI, crypto, and healthcare names that are experiencing impressive growth and bringing life-changing technology to consumers or other companies.
Here is the list of publicly traded companies or those that are part of a publicly traded company. It is broken down by the key groups used by Time: Innovators, Disruptors, Leaders, Titans and Pioneers.
Innovators
<ul class="wp-block-list">
<li>On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>): footwear</li>
<li>Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>): Chinese e-commerce</li>
<li>Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>): video games</li>
<li>BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>): electric vehicles</li>
<li>Gap, unit of Gap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>): apparel</li>
<li>Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>): sports and outdoor retailer</li>
<li>EssilorLuxottica (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESLOY#OTC">ESLOY</a>): sunglasses, optical wear</li>
</ul>
Disruptors
<ul class="wp-block-list">
<li>Waymo, unit of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
<li>Life Time Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>): fitness centers</li>
<li>Elf Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>): beauty products</li>
<li>Poppi, unit of PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): beverages</li>
<li>UFC, unit of TKO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>): fighting sports league</li>
<li>Pop Mart (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PMRTY#OTC">PMRTY</a>): pop culture retailer</li>
<li>Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): cryptocurrency trading platform</li>
<li>SharkNinja Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>): home appliances</li>
</ul>
Leaders
<ul class="wp-block-list">
<li>Engie (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ENGIY#OTC">ENGIY</a>): energy company</li>
<li>Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>): industrial and logistics real estate</li>
<li>Cloudflare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NET#NASDAQ">NET</a>): a software company</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): biotechnology, healthcare</li>
<li>Duolingo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>): mobile learning</li>
<li>BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>): financials</li>
<li>Hyundai Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>): automotives</li>
<li>LinkedIn, unit of Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): social networking</li>
<li>Coursera Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>): online learning</li>
</ul>
Titans
<ul class="wp-block-list">
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>): conglomerate</li>
<li>Comcast, NBC Universal, units of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): media and entertainment</li>
<li>L'Oreal (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LRLCY#OTC">LRLCY</a>): beauty company</li>
<li>DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>): food delivery</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): social networking</li>
<li>Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>): a software company</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): e-commerce</li>
<li>Arm Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>): semiconductors</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): consumer products</li>
<li>Fiserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): financial technology</li>
<li>MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>): Latin American e-commerce</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>): retailer</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>): streaming</li>
<li>Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>): semiconductors</li>
<li>Universal Music Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UNVGY#OTC">UNVGY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/UMGNF#OTC">UMGNF</a>): music publishing</li>
</ul>
Pioneers
<ul class="wp-block-list">
<li>ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>): semiconductors</li>
<li>Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>): oil and gas</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): medical devices</li>
<li>Softbank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>): telecom and e-commerce conglomerate</li>
<li>CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): gene editing</li>
</ul>
Read Also: <a href="https://www.benzinga.com/general/social-media/24/09/40760039/elon-musk-less-influential-to-artificial-intelligence-than-scarlett-johansson-time-magazine-">Elon Musk Less Influential To Artificial Intelligence Than Scarlett Johansson, Time Magazine Says: Billionaire Brushes Off Exclusion – &#8216;Magazines Do Not Establish Relevance, History Does&#8217;</a>
Why It's Important: Nearly half of this year's list includes companies that are publicly traded or part of publicly traded companies. This means investors can get exposure to what Time considers some of the most influential companies in the world.
Some of the companies are newer to the public market, which could mean that the 50+ companies that are not yet public could be among IPOs to watch for in the second half of 2025 and beyond.
Some of the most recognizable private companies on this year's list include OpenAI, Polymarket, Anthropic, Anduril, Beast Industries and SpaceX.
When seeking companies that can drive revenue growth and gain customer and consumer adoption, the most influential lists can be a valuable starting point for investors.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/03/44367926/mark-cuban-kevin-oleary-rejected-poppi-on-shark-tank-pepsi-just-paid-1-9-billion-to-acquire-company">Mark Cuban, Kevin O&#8217;Leary Rejected Poppi On Shark Tank, Pepsi Just Paid $1.9 Billion To Acquire Company</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

Media

AMZN

ASML

BABA

BYDDF

BYDDY

CMCSA

COIN

COUR

CRSP

DASH

DUOL

ENGIY

EQNR

ESLOY

GILD

GOOG

GOOGL

HYMTF

LRLCY

MELI

MSFT

NFLX

NTDOY

ONON

PLTR

PMRTY

SFTBF

SFTBY

UMGNF

UNVGY

44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy

<a href="https://www.bloomberg.com/news/articles/2025-06-27/opec-is-set-to-weigh-another-super-sized-oil-output-increase" title="https://www.bloomberg.com/news/articles/2025-06-27/opec-is-set-to-weigh-another-super-sized-oil-output-increase">https://www.bloomberg.com/news/articles/2025-06-27/opec-is-set-to-weigh-another-super-sized-oil-output-increase</a>

Global

'OPEC+ Is Set To Weigh Another Super-Sized Oil Output Increase' - Bloomberg News

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074819/PPIO.png" alt="" class="wp-image-14979" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074819/PPIO.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074819/PPIO-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27074819/PPIO-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The provider of cloud services wants to upgrade its systems as AI moves into the mainstream, demanding greater processing capacity and speed 
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The loss-making company has filed for an IPO to raise fresh funds to meet the anticipated growth in AI-related demand</li>
<li>It specializes in localized "edge" processing for faster response times, with revenues jumping 56% last year &nbsp;&nbsp;</li>
<li></li>
</ul>
As AI technology takes off, more computing power will be needed to apply generative learning to practical tasks and new contexts. This process, known in the industry as inference, could drive exponential demand for cloud services.
Gearing up for a fight over processing bandwidth, a Chinese provider of cloud services has applied to list on the Hong Kong Stock Exchange, with global ambitions to help empower the next phase of the AI revolution.
In its&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107464/documents/sehk25062001135.pdf">prospectus</a>, PPLabs Technology Ltd.,&nbsp;the parent of cloud services provider PPIO, cited plans to upgrade its AI-related services and develop its overseas presence in distributed cloud computing. The company describes itself as as pioneer of cloud services in China for AI tasks, ranking second among independent providers for average daily use.
The daily consumption rate in May reached 141.9 billion tokens, the system used by the computing industry to measure and price its operations.
<h4 class="wp-block-heading">Second chances</h4>
Company founder Yao Xin is no stranger to the tech industry. As a graduate student at Huazhong University of Science and Technology, Yao founded China's earliest online video platform in 2005. PPLive Media, later rebranded as PPTV, made its debut a year before YouTube, raising $700 million in capital before being sold to retailer Suning in 2014. At that point Yao paused his entrepreneurial activities.
Returning with the launch of PPIO in 2018, he focused the new business on an aspect of cloud computing that was not yet dominated by tech giants. The company set out to specialize in distributed edge computing, which aims to process data close to where it is generated.
The moves reflect shifting dynamics in cloud computing with the transformative advent of artificial intelligence. The costs of rolling out extrapolative AI systems and the challenge of allocating computing resources to them are causing bottlenecks. A capacity battle is brewing over the responsiveness to AI requests, in which edge computing can offer a proximity advantage.
Take the example of a Beijing user interacting with an AI assistant. If the task is handled at a U.S. data center, response delays are hard to avoid, even with optimized network transmission. However, a request routed via a node in Beijing or Hebei could be processed more like a real-time experience, which is particularly critical for voice, video, or gaming applications.
According to China Insights Consultancy, the edge cloud computing market in China is set to reach 37 billion yuan ($5.16 billion) in revenue by 2029, with a compound annual growth rate (CAGR) of 22.9% from 2024 to 2029. The global market was projected to achieve a CAGR of 68.5% over the same period, reaching 427.7 billion yuan in 2029.
Companies offering edge cloud services could become vital links in the AI industry chain, connecting infrastructure providers such as telecom operators with suppliers of processing hardware while packaging and distributing computing power along the way, and supporting AI developers.
PPIO has built a distributed computing network covering more than 1,200 cities and 4,000 nodes worldwide through its own infrastructure and partnerships.&nbsp; Using a scheduling platform developed in house, the network enables AI tasks to be automatically routed to the nearest available resource.
<h4 class="wp-block-heading">An Airbnb model?</h4>
The business monetizes the market in three ways. Firstly, computing power resources are provided to developers on demand, with billing based on duration or the tokens consumed. This income stream accounts for around 70% of revenue. In edge node services, idle hardware from enterprises or developers is co-opted into the node network, generating revenue through shared computing power. The company also offers customized AI applications, including services for small-model reasoning and systems to distribute content to nearby networks.
With its business still in the expansionary phase, PPIO has yet to break even. Still, it compares favorably to some cloud service startups, with relatively contained losses and a gross profit margin above 10%.
Figures in the IPO filing show that its turnover and losses have both been rising. The company logged revenues of 286 million yuan in 2022, increasing to 358 million yuan a year later and jumping nearly 56% in 2024 to 558 million yuan, a CAGR over the period of nearly 40%. Gross profit margins were 16.1%, 17.7% and 12.3%, while losses amounted to 85 million yuan, 189.4 million yuan and 293.5 million yuan, totaling around 568 million yuan for the three-year period.
The way PPIO aggregates idle processing resources and uses multi-node scheduling for AI tasks is similar to Airbnb approach of utilizing idle rooms. The PPIO model is suited for use with AI agents and for visual tasks or low-latency interactive scenarios.
However, distributed architectures also face challenges when it comes to regulation, standardization and service stability. Market competition is also intensifying, as major tech players step into the arena. Aside from direct rivals such as UCloud,&nbsp;Alibaba&nbsp;(BABA.US; 9988.HK),&nbsp;Baidu&nbsp;(BIDU.US; 9888.HK) &nbsp;and&nbsp;Kingsoft Cloud&nbsp;(3896.HK) are building up their own AI computing power and edge nodes. To maintain its position, PPIO would need to stay ahead of the game for platform experience, pricing and international reach.
To that end, PPIO does need external financing to keep expanding and to avoid a liquidity crunch, having around only 114 million yuan in cash on hand and a net debt of 696 million yuan.
The streaming service PPTV, which never went public, could be viewed as a missed opportunity for founder Yao. The cloud computing firm PPIO offers a second chance at stock market success, if the company can effectively plug into the surging demand for AI computing.

Asia

IPOs

PPIO Eyes Next AI Frontier With Plans To Boost Computing Power

Deutsche Bank analyst Matt Niknam initiates coverage on A10 Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) with a Buy rating and announces Price Target of $22.

Initiation

ATEN

Deutsche Bank Initiates Coverage On A10 Networks with Buy Rating, Announces Price Target of $22

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher after President Trump said the US signed a deal with China, with China's Ministry of Commerce reportedly confirming a trade framework. Israel-Iran ceasefire efforts and stronger-than-expected consumer sentiment data may also be lifting market outlook.

The U.S. Food and Drug Administration (FDA) approved label updates for Bristol Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) for large B cell lymphoma (LBCL) and other lymphomas and Abecma (idecabtagene vicleucel; ide-cel) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">for multiple myeloma</a>.
In the first quarter of 2025, Bristol Myers Squibb reported Abecam sales of $103 million, up 26% year over year, and Breyanzi sales <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44986472/bristol-myers-delivers-upbeat-2025-forecast-after-beating-q1-wall-street-expectations-says-guidance-includes-china-tariffs-impact" rel="noreferrer noopener">jumped 146% to $204 million</a>.
The company said in a statement on Thursday that these label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46131412/u-s-food-and-drug-administration-approves-streamlined-patient-monitoring-requirements-and-removal-" rel="noreferrer noopener">was initially approved</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/legal/25/06/46098969/bristol-myers-faces-scrutiny-for-allegedly-rigging-market-on-2b-cancer-drug" rel="noreferrer noopener">Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2 Billion Cancer Drug</a>
The company says about 2 in 10 eligible patients receive it due to the confluence of complex logistical and geographic barriers affecting patients and providers.
The FDA has approved the reduction or removal of specific patient monitoring requirements for Breyanzi and Abecma across both labels.
These prolonged requirements burdened healthcare delivery systems and certain patients and their care partners, particularly those who live far from certified cell therapy treatment centers.
Driving restrictions post-treatment have been reduced from eight weeks to two weeks. The requirement to remain within proximity of a healthcare facility after infusion has also been shortened from four weeks to two weeks.
The FDA has also approved the removal of the REMS requirement from each product label. A REMS program is often required to help mitigate known or potential risks associated with new drugs or therapies.
The FDA has since determined that the established management guidelines and extensive experience of the medical hematology/oncology community are sufficient to diagnose and manage the risks of side effects, including cytokine release syndrome (CRS) and neurologic toxicities (NTs), without a REMS for the class of CD19- and BCMA-directed autologous CAR T cell therapies.
In April 2024, the FDA said it would now&nbsp;require boxed warnings, the highest safety-related caution for medications, for all chimeric antigen <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38334543/fda-mandates-boxed-warning-for-bristol-myers-johnson-johnson-car-t-based-blood-cancer-therapies" rel="noreferrer noopener">receptor (CAR) T-cell therapies</a>.&nbsp;
According to the agency, these blood cancer treatments may pose a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-" rel="noreferrer noopener">risk of secondary cancers</a>.
Price Action: BMY stock is trading higher by 0.40% to $46.84 last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46139132/spain-accuses-novo-nordisk-of-covert-advertising-for-prescription-weight-loss-drugs" target="_blank" rel="noreferrer noopener">Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers

Press Releases

Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to Present at Multiple March Investor Conferences

Earnings

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Comments

Oruka Therapeutics

Noticias

Últimas noticias sobre Oruka Therapeutics (NASDAQ:ORKA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL